Literature DB >> 8565996

Criteria for testing the susceptibility of Streptococcus pneumoniae to cefotaxime and its desacetyl metabolite using 1 microgram or 30 micrograms cefotaxime disks.

A L Barry1, S D Brown, W J Novick.   

Abstract

In vitro susceptibility tests were performed with 350 selected strains of Streptococcus pneumoniae to evaluate disk diffusion tests with 30 micrograms and 1 microgram cefotaxime disks. Zones were compared to MICs of cefotaxime with and without its desacetyl metabolite. Cefotaxime was two to eight times more active than desacetyl cefotaxime, but the two compounds were additive when combined in vitro. For 30 micrograms disks, zone size breakpoints were < or = 27 mm, 28-30 mm and > or = 31 mm for resistant, intermediate and susceptible, respectively. For 1 microgram disks, those zone size criteria were reduced to < or = 13 mm, 14-16 mm and > or = 17 mm. The 30 micrograms disk that is currently available for testing other species can be used for testing pneumococci; however, the 1 microgram disk has some important advantages.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8565996     DOI: 10.1007/bf01690885

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  8 in total

Review 1.  Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.

Authors:  M R Jacobs
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

2.  Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to beta-lactam antibiotics.

Authors:  J S Bradley; J D Connor
Journal:  Pediatr Infect Dis J       Date:  1991-11       Impact factor: 2.129

Review 3.  Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review.

Authors:  C C John
Journal:  Clin Infect Dis       Date:  1994-02       Impact factor: 9.079

4.  Concentrations of cefotaxime and the desacetyl metabolite in serum and CSF of patients with meningitis.

Authors:  G Humbert; A Leroy; S R Nair; C E Cherubin
Journal:  J Antimicrob Chemother       Date:  1984-05       Impact factor: 5.790

5.  Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis.

Authors:  M M Sloas; F F Barrett; P J Chesney; B K English; B C Hill; F C Tenover; R J Leggiadro
Journal:  Pediatr Infect Dis J       Date:  1992-08       Impact factor: 2.129

6.  Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

7.  Meningitis due to penicillin-resistant Streptococcus pneumoniae in adults.

Authors:  R D Weingarten; Z Markiewicz; D N Gilbert
Journal:  Rev Infect Dis       Date:  1990 Jan-Feb

8.  Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae.

Authors:  M J Catalán; J M Fernández; A Vazquez; E Varela de Seijas; A Suárez; J C Bernaldo de Quirós
Journal:  Clin Infect Dis       Date:  1994-05       Impact factor: 9.079

  8 in total
  4 in total

1.  Use of an oxacillin disk screening test for detection of penicillin- and ceftriaxone-resistant pneumococci.

Authors:  L P Jetté; C Sinave
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

2.  Surrogate disks for predicting cefotaxime and ceftriaxone susceptibilities of Streptococcus pneumoniae.

Authors:  A L Barry; P C Fuchs
Journal:  J Clin Microbiol       Date:  1996-10       Impact factor: 5.948

3.  Selection of zone size interpretive criteria for disk diffusion susceptibility tests of three antibiotics against Streptococcus pneumoniae, using the New Guidelines of the National Committee for Clinical Laboratory Standards.

Authors:  Peter C Fuchs; Arthur L Barry; Steven D Brown
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

4.  Predicting susceptibility of Streptococcus pneumoniae to ceftriaxone and cefotaxime by cefuroxime and ceftizoxime disk diffusion testing.

Authors:  N Williams-Bouyer; A Hernandez; B S Reisner
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.